Palisade Capital Management’s Krystal Biotech KRYS Stock Holding History

Palisade Capital Management’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.74M	Buy	+10,065	New	+$3.01M	0.16%	173

Other funds holding KRYS

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Palisade Capital Management's KRYS Position: Q2 2026 in Review

Palisade Capital Management opened a new position in Krystal Biotech (KRYS) in Q2 2026: 10,065 shares worth $3.74M. The stake represents 0.16% of the portfolio and ranks #173 among its holdings.

422 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

Palisade Capital Management held 10,065 shares of Krystal Biotech worth $3.74M as of Q2 2026.
Krystal Biotech was a new Palisade Capital Management position in Q2 2026.
Krystal Biotech made up 0.16% of Palisade Capital Management's portfolio in Q2 2026, its #173 holding.
422 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Palisade Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.